Active Ingredient History
Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Aplastic (Phase 2)
Anemia, Diamond-Blackfan (Phase 2)
Arthritis, Juvenile (Phase 2)
Asthma (Phase 2)
Behcet Syndrome (Phase 2)
Brain Neoplasms (Phase 1)
Choroidal Neovascularization (Phase 2)
Colitis, Ulcerative (Phase 2)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetes Mellitus, Type 2 (Phase 2)
DiGeorge Syndrome (Phase 2)
End Stage Liver Disease (Phase 4)
Fibrosis (Phase 4)
Gastrointestinal Diseases (Phase 2)
Graft vs Host Disease (Phase 4)
Granulomatosis with Polyangiitis (Phase 2)
Healthy Volunteers (Phase 1)
Heart Transplantation (Phase 4)
Hepatitis C (Phase 4)
HIV Infections (Phase 1)
HTLV-I Infections (Phase 1/Phase 2)
Hypoglycemia (Phase 2)
Immunosuppression Therapy (Phase 4)
Inflammatory Bowel Diseases (Phase 2)
Iritis (Phase 2)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Leukemia (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 4)
Leukemia, T-Cell (Phase 1/Phase 2)
Liver Transplantation (Phase 2)
Living Donors (Phase 4)
Lung Transplantation (Phase 3)
Lymphoma (Phase 2)
Macular Degeneration (Phase 2)
Melanoma (Phase 1/Phase 2)
Metabolic Diseases (Phase 2)
Multiple Myeloma (Phase 2)
Multiple Sclerosis (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Plasmapheresis (Phase 4)
Psoriasis (Phase 1/Phase 2)
Red-Cell Aplasia, Pure (Phase 2)
Renal Insufficiency (Phase 4)
Retinal Diseases (Phase 2)
Thrombocytopenia (Phase 2)
Transplantation (Phase 4)
Uveitis (Phase 2)
Uveitis, Anterior (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
